Cinclus Pharma (CINPHA.ST) stock: key figures, P/E, revenue and dividend

Health Care · Sweden · ISIN SE0020388577

Price
12.00 SEK
Market cap
558.45 m SEK
P/E (2025)
–
P/S (2025)
9.72
Dividend yield
0.00 %
Net margin
-320.12 %
Return on equity (ROE)
-49.80 %
Return on assets (ROA)
-33.66 %

Cinclus Pharma financials

Fiscal year20242025
Revenue4.58 m SEK57.47 m SEK
Operating income-168.93 m SEK-198.18 m SEK
EBIT-158.56 m SEK-183.32 m SEK
Net income-168.03 m SEK-183.97 m SEK
Diluted EPS – continuing operations-3.61 SEK-3.95 SEK

Full history since 2022, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Cinclus Pharma

Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori. Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.